NCT00504270View on ClinicalTrials.gov

A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions

Psoriasis

Interventions

DRUG

Placebo

po daily

DRUG

RG3421 120mg

120mg po daily

DRUG

RG3421 20mg

20mg po daily

Trial Locations (15)

10016

New York

10029

New York

11790

Stony Brook

27157

Winston-Salem

30005

Alpharetta

37215

Nashville

71913

Hot Springs

72205

Little Rock

77550

Galveston

77598

Webster

78229

San Antonio

87106

Albuquerque

90404

Santa Monica

08520

East Windsor

02903

Providence

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT00504270 - A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis. | Biotech Hunter | Biotech Hunter